Pages that link to "Q33598299"
Jump to navigation
Jump to search
The following pages link to High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease (Q33598299):
Displaying 50 items.
- Recombinant Human Acid α-Glucosidase Corrects Acidα-Glucosidase-Deficient Human Fibroblasts, Quail Fibroblasts, and Quail Myoblasts (Q24317595) (← links)
- Recombinant human sulphamidase: expression, amplification, purification and characterization (Q24530626) (← links)
- Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail (Q24564823) (← links)
- New insights into therapeutic options for Pompe disease (Q26851649) (← links)
- Modulation of disease severity in mice with targeted disruption of the acid alpha-glucosidase gene (Q28587632) (← links)
- Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II (Q28592264) (← links)
- Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease (Q30489156) (← links)
- Towards a molecular therapy for glycogen storage disease type II (Pompe disease). (Q33935462) (← links)
- Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations (Q34214905) (← links)
- Pompe disease diagnosis and management guideline. (Q34567528) (← links)
- Enzyme therapy for Pompe disease: from science to industrial enterprise (Q34954692) (← links)
- Pompe disease: literature review and case series (Q35029971) (← links)
- Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase (Q35586463) (← links)
- Enzyme replacement and enhancement therapies for lysosomal diseases (Q35800534) (← links)
- Glycogen storage disease types I and II: treatment updates (Q36739605) (← links)
- Carbohydrate Structures of Recombinant Human α-l-Iduronidase Secreted by Chinese Hamster Ovary Cells (Q36879990) (← links)
- Pompe disease: current state of treatment modalities and animal models. (Q36934500) (← links)
- Progress and problems when considering gene therapy for GSD-II. (Q36960374) (← links)
- Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants (Q37040458) (← links)
- Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II. (Q37259816) (← links)
- A review of treatment of Pompe disease in infants (Q37290516) (← links)
- Pompe's disease (Q37302098) (← links)
- A Modified Enzymatic Method for Measurement of Glycogen Content in Glycogen Storage Disease Type IV. (Q37415869) (← links)
- Challenges in diagnosis and treatment of late-onset Pompe disease (Q37926444) (← links)
- Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice (Q38327807) (← links)
- Enzymes approved for human therapy: indications, mechanisms and adverse effects (Q38342838) (← links)
- Biosynthesis, glycosylation, and enzymatic processing in vivo of human tripeptidyl-peptidase I. (Q38359647) (← links)
- Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives (Q38684097) (← links)
- Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease (Q38982768) (← links)
- Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. (Q40483404) (← links)
- Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency (Q40644692) (← links)
- Long-term correction of glycogen storage disease type II with a hybrid Ad-AAV vector (Q40669141) (← links)
- Translocon pores in the endoplasmic reticulum are permeable to a neutral, polar molecule (Q42502796) (← links)
- Structure of human lysosomal acid α-glucosidase-a guide for the treatment of Pompe disease. (Q42645986) (← links)
- Expression of Mutant Dynamin Inhibits Toxicity and Transport of Endocytosed Ricin to the Golgi Apparatus (Q42837745) (← links)
- Multiple muscles in the AMD quail can be “cross‐corrected” of pathologic glycogen accumulation after intravenous injection of an [E1‐, polymerase‐] adenovirus vector encoding human acid‐α‐glucosidase (Q43966323) (← links)
- Enzyme replacement therapy in the mouse model of Pompe disease (Q44624370) (← links)
- Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor (Q45133882) (← links)
- Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. (Q45259698) (← links)
- Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter (Q45457148) (← links)
- Packaging of an AAV vector encoding human acid α-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector (Q45862016) (← links)
- Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model (Q45877711) (← links)
- Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease (Q46484079) (← links)
- Short-term, high dose enzyme replacement therapy in sialidosis mice (Q46567099) (← links)
- Stabilising normal and mis-sense variant alpha-glucosidase (Q51805825) (← links)
- Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. (Q55034196) (← links)
- Retroviral Transfer of Acidα-Glucosidase cDNA to Enzyme-Deficient Myoblasts Results in Phenotypic Spread of the Genotypic Correction by Both Secretion and Fusion (Q73758781) (← links)
- The use of acarbose inhibition in the measurement of acid alpha-glucosidase activity in blood lymphocytes for the diagnosis of Pompe disease (Q83350404) (← links)
- Antibody-Mediated Enzyme Therapeutics and Applications in Glycogen Storage Diseases (Q90114493) (← links)
- Assessing metabolic profiles in human myoblasts from patients with late-onset Pompe disease (Q92487762) (← links)